March 26th 2024
The agency submits complete response letters based on the enrollment status of confirmatory trials for odronextamab in follicular lymphoma and diffuse large B-cell lymphoma.
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Polatuzumab Vedotin Demonstrates Tolerable Safety Profile in Aggressive LBCLs
August 25th 2023Data indicate that replacement of vincristine with polatuzumab vedotin in combination with etoposide, prednisone, cyclophosphamide, doxorubicin, and rituximab should be further explored in large B-cell lymphoma.
FDA Issues CRL for Denileukin Diftitox in R/R Cutaneous T-Cell Lymphoma
July 31st 2023The regulatory agency requests enhanced product testing and additional controls in their market application review of denileukin diftitox for the treatment of those with relapsed/refractory cutaneous T-cell lymphoma.
Polatuzumab Vedotin Plus R-mini-CHOP Does not Increase High-Grade AEs in DLBCL
June 10th 2023Replacing vincristine with polatuzumab vedotin in R-mini-CHOP, although it hasn’t increased grade 3/4 hematologic toxicity, may increase gastrointestinal adverse effects in a cohort of frail patients with diffuse large B-cell lymphoma.